Compare CSPI & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | PMN |
|---|---|---|
| Founded | 1968 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.1M | 115.5M |
| IPO Year | 1994 | 2022 |
| Metric | CSPI | PMN |
|---|---|---|
| Price | $9.17 | $11.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 11.9K | ★ 34.1K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $908.00 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.55 | $0.29 |
| 52 Week High | $17.76 | $27.40 |
| Indicator | CSPI | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 35.71 |
| Support Level | $8.89 | $10.57 |
| Resistance Level | $9.09 | $19.85 |
| Average True Range (ATR) | 0.54 | 1.36 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 61.57 | 20.68 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.